Investigating the synergistic mechanism between ibrutinib and daunorubicin in acute myeloid leukemia cells

Lianne E. RotinPrincess Margaret Cancer Centre, Ontario Cancer Institute, University Health Network, Toronto, ON, Canada; ;Institute of Medical Science, University of Toronto, Toronto, ON, Canada;

Marcela GrondaPrincess Margaret Cancer Centre, Ontario Cancer Institute, University Health Network, Toronto, ON, Canada;

Rose HurrenPrincess Margaret Cancer Centre, Ontario Cancer Institute, University Health Network, Toronto, ON, Canada;

XiaoMing WangPrincess Margaret Cancer Centre, Ontario Cancer Institute, University Health Network, Toronto, ON, Canada;

Mark D. MindenPrincess Margaret Cancer Centre, Ontario Cancer Institute, University Health Network, Toronto, ON, Canada;

Malik SlassiFluorinov Pharma Inc., Toronto, ON, Canada

Aaron D. SchimmerPrincess Margaret Cancer Centre, Ontario Cancer Institute, University Health Network, Toronto, ON, Canada; ;Institute of Medical Science, University of Toronto, Toronto, ON, Canada; Correspondence[email protected]

show all

Click to increase image sizeClick to decrease image size

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article at http://dx.doi.org/10.3109/10428194.2016.1138292.

Funding information

This work was funded by the Leukemia and Lymphoma Society of Canada, the Canadian Stem Cell Network, the Canadian Institutes of Health Research (CIHR), the Princess Margaret Cancer Centre Foundation, and the Ministry of Long Term Health and Planning in the Province of Ontario. LER was supported by a CIHR Frederick Banting and Charles Best Canada Graduate Scholarship, CIHR MD/PhD Studentship, Peterborough KM Hunter Graduate Studentship, and Hernandez Family Oncology MD/PhD Fellowship. ADS holds the Baker Chair in Leukemia and Related Diseases.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Investigating the synergistic mechanism between ibrutinib and daunorubicin in acute myeloid leukemia cells

Potential conflict of interest

Information for

Open access

Opportunities

Help and information

Investigating the synergistic mechanism between ibrutinib and daunorubicin in acute myeloid leukemia cells

Potential conflict of interest

Funding information

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature